INOVIQ Ltd
ASX:IIQ

Watchlist Manager
INOVIQ Ltd Logo
INOVIQ Ltd
ASX:IIQ
Watchlist
Price: 0.395 AUD Market Closed
Market Cap: 55.6m AUD

INOVIQ Ltd
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

INOVIQ Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
INOVIQ Ltd
ASX:IIQ
Net Income (Common)
-AU$6.9m
CAGR 3-Years
28%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Sonic Healthcare Ltd
ASX:SHL
Net Income (Common)
AU$513.6m
CAGR 3-Years
-29%
CAGR 5-Years
-1%
CAGR 10-Years
4%
Integral Diagnostics Ltd
ASX:IDX
Net Income (Common)
AU$4.7m
CAGR 3-Years
-32%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Capitol Health Ltd
ASX:CAJ
Net Income (Common)
-AU$14.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Australian Clinical Labs Ltd
ASX:ACL
Net Income (Common)
AU$32.4m
CAGR 3-Years
-43%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
H
Healius Ltd
ASX:HLS
Net Income (Common)
-AU$151.2m
CAGR 3-Years
N/A
CAGR 5-Years
-16%
CAGR 10-Years
N/A
No Stocks Found

INOVIQ Ltd
Glance View

Market Cap
55.6m AUD
Industry
Health Care

INOVIQ Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is focused on developing and commercializing a portfolio of diagnostic and exosome-based solutions to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Company’s products include hTERT ICC test, which is an immunocytochemistry (ICC) assay that detects hTERT and is used as an adjunct to urine cytology, and EXO-NET RUO, which is a pan-exosome capture tool for isolation of exosomes from body fluids including plasma, urine, and saliva. The company is also developing solutions using SubB2M, NETs, BARD1 and hTERT technologies to improve patient health outcomes.

IIQ Intrinsic Value
0.111 AUD
Overvaluation 72%
Intrinsic Value
Price

See Also

What is INOVIQ Ltd's Net Income (Common)?
Net Income (Common)
-6.9m AUD

Based on the financial report for Jun 30, 2025, INOVIQ Ltd's Net Income (Common) amounts to -6.9m AUD.

What is INOVIQ Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-16%

Over the last year, the Net Income (Common) growth was -6%. The average annual Net Income (Common) growth rates for INOVIQ Ltd have been 28% over the past three years , -16% over the past five years .

Back to Top